Covid-19 was the primary or contributing cause of 377,883 deaths in the United States during 2021, with a particularly high toll among the elderly, according to a government report released on March 31.

Linda von Rosenvinge, IQ Practice Lead of Greater Than One, explores some of the reasons behind data mishaps and recommends remedies every healthcare marketer can incorporate into their research protocols. 

California surpassed New York on Feb. 9 as the U.S. state with the most coronavirus deaths, a grim reminder of the pandemic’s toll even as the vaccine rollout and a sharp drop in new cases buoyed hopes of life eventually returning to normal.

A final analysis of the Phase III TITAN study shows that Janssen’s Erleada (apalutamide), when added to androgen deprivation therapy, significantly improved overall survival in patients with metastatic castration-sensitive prostate cancer (mCSPC) compared with placebo.

Once touted as promising treatments and by some even a cure, the World Health Organization dashes those claims, finding no benefit in the use of four popular Covid-19 treatments (remdesivir, hydroxychloroquine, lopinavir, or interferon-beta-1a) on hospitalized patients.  

A study showed the use of convalescent plasma provided no clinical benefit nor improved mortality in Covid-19 patients with pneumonia.

Chicago’s mayor issued a month-long stay-at-home advisory, and Detroit’s public schools called a halt to in-person instruction to curb the spread of the coronavirus as more than a dozen U.S. states reported a doubling of new Covid-19 cases in the last two weeks.

Gilead Sciences Inc.’s remdesivir had little or no effect on Covid-19 patients’ length of hospital stay or chances of survival, a clinical trial by the World Health Organization (WHO) found.

Final data from Gilead Sciences Inc.’s antiviral drug remdesivir showed the treatment cut Covid-19 recovery time by five days compared with patients who got a placebo, one day faster than indicated in preliminary data, the company and researchers said.

After a disappointing end to a nine-year trial, the U.S. Food and Drug Administration officially gave AMAG Pharmaceuticals notice of the proposal to withdraw approval of Makena, an injectable progestin treatment to reduce preterm births.